Notification
No new Notification messages
Hyundai Motor India IPO is Open!
Apply for the Hyundai Motor India IPO through UPI in just minutes
HCL Technologies Q2 Results FY'25
HCL Tech announced its Q2 FY'25 results, revenue jumped by 8.2% YoY at ₹28,862 crores, and Net Income stood at ₹4,235 crores up 10.5% YoY.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
Trade Now, Pay Later with up to 4x Leverage
Never miss a good trading opportunity due to low funds with our MTF feature.
NSE BSE
venus remedies limited stock

VENUS REMEDIES LIMITED Share Price

346.6 -2.50 (-0.71%)
Oct 16 2024 09:15 AM Pharmaceuticals NSE: VENUSREM

VENUS REMEDIES LIMITED Share Price Update

As of the latest trading session, VENUS REMEDIES LIMITED share price is currently at 346.6, which is down by -2.50 from its previous closing. Today, the stock has fluctuated between 346.00 and 352.00. Over the past year, VENUS REMEDIES LIMITED has achieved a return of 25.79 %. In the last month alone, the return has been -2.74 %. Read More...

VENUS REMEDIES LIMITED Performance

Day Range

Low346.00 High352.00
349.10

52 Week Range

Low 226.25 High 430.00
349.10

VENUS REMEDIES LIMITED Share Price

13859

526953

VENUSREM

img img img img
No Data Available

Open Price

349.00

Prev. Close

349.10

Volume (Shares)

41498.00

Total traded value

144.86

Upper Circuit

418.90

Lower Circuit

279.30

Note: The current prices & values are delayed, Login to your account for live updates.

VENUS REMEDIES LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 463.29
PE Ratio (TTM) 15.00
Book Value / Share 380.48
Beta 0.68
ROE 6.18%
EPS (TTM) 22.89
Dividend Yield 0.00%
Net Profit Qtr (Cr) 4.45

VENUS REMEDIES LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars JUN 2024 (Values in Cr)
Revenue 105.86
Operating Expense 97.34
Net Profit 4.45
Net Profit Margin (%) 4.20
Earnings Per Share (EPS) 3.33
EBITDA 15.84
Effective Tax Rate (%) 55.85
Particulars MAR 2024 (Values in Cr)
Revenue 175.16
Operating Expense 159.61
Net Profit 12.51
Net Profit Margin (%) 7.14
Earnings Per Share (EPS) 9.36
EBITDA 25.18
Effective Tax Rate (%) 35.71
Particulars DEC 2023 (Values in Cr)
Revenue 131.23
Operating Expense 124.53
Net Profit 8.19
Net Profit Margin (%) 6.24
Earnings Per Share (EPS) 6.13
EBITDA 15.41
Effective Tax Rate (%) 10.19
Particulars SEP 2023 (Values in Cr)
Revenue 170.19
Operating Expense 163.27
Net Profit 5.45
Net Profit Margin (%) 3.20
Earnings Per Share (EPS) 4.07
EBITDA 16.06
Effective Tax Rate (%) 44.67
Particulars JUN 2023 (Values in Cr)
Revenue 98.63
Operating Expense 92.48
Net Profit 4.34
Net Profit Margin (%) 4.40
Earnings Per Share (EPS) 3.25
EBITDA 15.53
Effective Tax Rate (%) 47.13
Particulars MAR 2024 (Values in Cr)
Revenue 575.21
Operating Expense 539.88
Net Profit 30.50
Net Profit Margin (%) 5.30
Earnings Per Share (EPS) 22.82
EBITDA 72.20
Effective Tax Rate (%) 34.61
Particulars MAR 2023 (Values in Cr)
Revenue 537.66
Operating Expense 507.50
Net Profit 28.96
Net Profit Margin (%) 5.38
Earnings Per Share (EPS) 21.67
EBITDA 71.70
Effective Tax Rate (%) 28.19
Particulars MAR 2022 (Values in Cr)
Revenue 576.71
Operating Expense 540.47
Net Profit 48.99
Net Profit Margin (%) 8.49
Earnings Per Share (EPS) 37.12
EBITDA 77.25
Effective Tax Rate (%) -9.67
Particulars MAR 2021 (Values in Cr)
Revenue 514.62
Operating Expense 514.77
Net Profit 54.27
Net Profit Margin (%) 10.54
Earnings Per Share (EPS) 43.97
EBITDA 88.07
Effective Tax Rate (%) -32.17
Particulars MAR 2020 (Values in Cr)
Revenue 320.23
Operating Expense 321.26
Net Profit -8.23
Net Profit Margin (%) -2.57
Earnings Per Share (EPS) -6.67
EBITDA 37.84
Effective Tax Rate (%) -31.30
Particulars MAR 2024 (Values in Cr)
Book Value / Share 364.74
ROE % 6.01
ROCE % 8.52
Total Debt to Total Equity 0.09
EBITDA Margin 11.83
Particulars MAR 2023 (Values in Cr)
Book Value / Share 344.38
ROE % 5.90
ROCE % 7.59
Total Debt to Total Equity 0.09
EBITDA Margin 12.66
Particulars MAR 2022 (Values in Cr)
Book Value / Share 329.50
ROE % 9.69
ROCE % 7.76
Total Debt to Total Equity 0.11
EBITDA Margin 11.73
Particulars MAR 2021 (Values in Cr)
Book Value / Share 313.18
ROE % 10.59
ROCE % 7.55
Total Debt to Total Equity 0.38
EBITDA Margin 13.39
Particulars MAR 2020 (Values in Cr)
Book Value / Share 262.01
ROE % -0.96
ROCE % 2.38
Total Debt to Total Equity 0.79
EBITDA Margin 13.60
Particulars MAR 2024 (Values in Cr)
Book Value / Share 380.48
ROE % 6.18
ROCE % 8.61
Total Debt to Total Equity 0.08
EBITDA Margin 12.55
Particulars MAR 2023 (Values in Cr)
Book Value / Share 357.63
ROE % 6.24
ROCE % 7.89
Total Debt to Total Equity 0.08
EBITDA Margin 13.34
Particulars MAR 2022 (Values in Cr)
Book Value / Share 336.21
ROE % 11.53
ROCE % 9.39
Total Debt to Total Equity 0.10
EBITDA Margin 13.39
Particulars MAR 2021 (Values in Cr)
Book Value / Share 313.10
ROE % 8.42
ROCE % 6.00
Total Debt to Total Equity 0.36
EBITDA Margin 12.56
Particulars MAR 2020 (Values in Cr)
Book Value / Share 269.21
ROE % -0.41
ROCE % 2.61
Total Debt to Total Equity 0.76
EBITDA Margin 14.57
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 68.09
Total Assets 626.82
Total Liabilities 626.82
Total Equity 487.55
Share Outstanding 13366988
Price to Book Ratio 0.86
Return on Assets (%) 4.54
Return on Capital (%) 5.39
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 54.44
Total Assets 601.08
Total Liabilities 601.08
Total Equity 460.33
Share Outstanding 13366988
Price to Book Ratio 0.45
Return on Assets (%) 4.41
Return on Capital (%) 5.29
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 50.39
Total Assets 579.81
Total Liabilities 579.81
Total Equity 440.44
Share Outstanding 13366988
Price to Book Ratio 0.80
Return on Assets (%) 7.02
Return on Capital (%) 8.43
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 31.41
Total Assets 555.85
Total Liabilities 555.85
Total Equity 400.28
Share Outstanding 12341988
Price to Book Ratio 0.88
Return on Assets (%) 11.11
Return on Capital (%) 13.68
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.12
Total Assets 643.77
Total Liabilities 643.77
Total Equity 323.37
Share Outstanding 12341988
Price to Book Ratio 0.08
Return on Assets (%) -1.55
Return on Capital (%) -2.08
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 67.64
Total Assets 641.26
Total Liabilities 641.26
Total Equity 508.59
Share Outstanding 13366988
Price to Book Ratio 0.86
Return on Assets (%) 4.75
Return on Capital (%) 5.57
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 53.30
Total Assets 608.89
Total Liabilities 608.89
Total Equity 478.04
Share Outstanding 13366988
Price to Book Ratio 0.45
Return on Assets (%) 4.75
Return on Capital (%) 5.61
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 49.96
Total Assets 578.66
Total Liabilities 578.66
Total Equity 449.41
Share Outstanding 13366988
Price to Book Ratio 0.80
Return on Assets (%) 8.46
Return on Capital (%) 10.04
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 30.24
Total Assets 546.81
Total Liabilities 546.81
Total Equity 400.18
Share Outstanding 12341988
Price to Book Ratio 0.88
Return on Assets (%) 9.92
Return on Capital (%) 12.12
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.44
Total Assets 644.26
Total Liabilities 644.26
Total Equity 332.25
Share Outstanding 12341988
Price to Book Ratio 0.08
Return on Assets (%) -1.27
Return on Capital (%) -1.69
Particulars MAR 2024 (Values in Cr)
Net Income 44.64
Cash from Operations 52.76
Cash from Investing -7.20
Cash from Financing -1.08
Net change in Cash 28.99
Free Cash Flow 62.08
Particulars MAR 2023 (Values in Cr)
Net Income 37.93
Cash from Operations 36.62
Cash from Investing -50.82
Cash from Financing -0.56
Net change in Cash -14.76
Free Cash Flow 44.44
Particulars MAR 2022 (Values in Cr)
Net Income 36.40
Cash from Operations 41.10
Cash from Investing -16.72
Cash from Financing -9.47
Net change in Cash 14.89
Free Cash Flow 41.10
Particulars MAR 2021 (Values in Cr)
Net Income 25.11
Cash from Operations 108.39
Cash from Investing 56.49
Cash from Financing -162.24
Net change in Cash 26.08
Free Cash Flow 108.39
Particulars MAR 2020 (Values in Cr)
Net Income 0.77
Cash from Operations 63.16
Cash from Investing -4.74
Cash from Financing -73.00
Net change in Cash -0.14
Free Cash Flow 70.94
Particulars MAR 2024 (Values in Cr)
Net Income 46.65
Cash from Operations 50.86
Cash from Investing -6.94
Cash from Financing 0.00
Net change in Cash 28.43
Free Cash Flow 59.91
Particulars MAR 2023 (Values in Cr)
Net Income 40.32
Cash from Operations 28.05
Cash from Investing -50.81
Cash from Financing 0.00
Net change in Cash -22.75
Free Cash Flow 35.85
Particulars MAR 2022 (Values in Cr)
Net Income 44.67
Cash from Operations 41.00
Cash from Investing -16.75
Cash from Financing -9.12
Net change in Cash 15.12
Free Cash Flow 54.68
Particulars MAR 2021 (Values in Cr)
Net Income 17.61
Cash from Operations 108.89
Cash from Investing 55.98
Cash from Financing -161.87
Net change in Cash 26.44
Free Cash Flow 108.89
Particulars MAR 2020 (Values in Cr)
Net Income 2.54
Cash from Operations 63.30
Cash from Investing -4.63
Cash from Financing -72.34
Net change in Cash 0.75
Free Cash Flow 70.97
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 61.28 39.79 3.42 469.61 35.27 / 77.70
BLISS GVS PHARMA LTD 127.25 13.11 1.38 1339.97 77.65 / 148.95
CIPLA LTD 1599.80 29.07 4.83 129194.57 1132.00 / 1702.00
FERMENTA BIOTECH LIMITED 313.45 0.00 3.19 922.51 144.45 / 332.50
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 61.28 92.85 11.65 469.61 35.27 / 77.70
AMRUTAJAN HEALTH LTD 762.80 51.79 7.64 2205.30 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 7671.40 146.40 26.93 19178.50 4050.15 / 8139.85
BLISS GVS PHARMA LTD 127.25 13.73 1.35 1339.97 77.65 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 334.80
  • 26 Days 340.60
  • 10 Days 334.50
  • 50 Days 354.60
  • 12 Days 335.00
  • 100 Days 346.60
  • 20 Days 338.30
  • 200 Days 383.40
340.87
PIVOT
First Resistance 349.33
Second Resistance 355.37
Third Resistance 363.83
First Support 334.83
Second Support 326.37
Third Support 320.33
RSI 49.94
MACD -5.55
Commodity Channel Index (CCI) 12.93
ADX 12.93
Williams % R -32.30

Over 1 Month

down

-2.74

Over 3 Months

down

-9.89

Over 6 Months

down

6.84

Over 1 Year

down

25.79

Over 3 Years

down

-5.94

Over 5 Years

down

73.39

VENUS REMEDIES LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

VENUS REMEDIES LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
57.06
Promoter Holdings
41.75
FII
1.17
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Sunev Pharma Solutions Limited Shareholding of Promoter and Promoter Group 2300000.0 17.21
Pawan Chaudhary Shareholding of Promoter and Promoter Group 1713946.0 12.82
Manu Chaudhary Shareholding of Promoter and Promoter Group 1568000.0 11.73
Mc Jain Infoservices Private Limited Public Shareholding 310000.0 2.32
Pradeep Kumar Jain Public Shareholding 267240.0 2.0
K.b.shekar Public Shareholding 262680.0 1.97
Acadian Emerging Markets Micro-cap Equity Master Fund Public Shareholding 147501.0 1.1
Ashutosh Jain Shareholding of Promoter and Promoter Group 0.0 0.0
Akshansh Chaudhary Shareholding of Promoter and Promoter Group 1.0 0.0
Peeyush Jain Shareholding of Promoter and Promoter Group 50.0 0.0

VENUS REMEDIES LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2013-09-23 3.0 Final 2013-09-25 Equity shares 2012-09-20 3.0 Final 2012-09-24 Equity shares 2011-09-22 3.0 Final 2011-09-25 Equity shares 2010-09-23 3.0 Final 2010-09-25 Equity shares 2009-09-17 3.0 Final 2009-09-20 Equity shares 2008-09-12 4.0 Final 2008-09-16 Equity shares 2007-09-18 3.0 Final 2007-09-20 Equity shares
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About VENUS REMEDIES LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by VENUS REMEDIES LIMITED

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Venus Remedies Ltd?

Answer Field

The share price of Venus Remedies Ltd for NSE is ₹ 346.6 and for BSE is ₹ 349.

What is the Market Cap of Venus Remedies Ltd?

Answer Field

The market cap of Venus Remedies Ltd for NSE is ₹ 4,63.29 Cr. and for BSE is ₹ 4,66.50 Cr. as of now.

What is the 52 Week High and Low of Venus Remedies Ltd?

Answer Field

The 52 Week High and Low of Venus Remedies Ltd for NSE is ₹ 430.00 and ₹ 226.25 and for BSE is ₹ 429.60 and ₹ 227.00.

How to Buy Venus Remedies Ltd share?

Answer Field

You can trade in Venus Remedies Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Venus Remedies Ltd?

Answer Field

The 1 year returns on the stock has been 25.79%.

What is the Current Share Price of Venus Remedies Ltd?

Answer Field

Venus Remedies Ltd share price is for NSE ₹ 346.6 & for BSE ₹ 349 as on Oct 16 2024 09:15 AM.

What is the Market Cap of Venus Remedies Ltd Share?

Answer Field

The market cap of Venus Remedies Ltd for NSE ₹ 4,63.29 & for BSE ₹ 4,66.50 as on Oct 16 2024 09:15 AM.

What is the P/E Ratio of Venus Remedies Ltd Share?

Answer Field

As on Oct 16 2024 09:15 AM the price-to-earnings (PE) ratio for Venus Remedies Ltd share is 15.00.

What is the PB ratio of Venus Remedies Ltd Share?

Answer Field

As on Oct 16 2024 09:15 AM, the price-to-book (PB) ratio for Venus Remedies Ltd share is 380.48.

How to Buy Venus Remedies Ltd Share?

Answer Field

You can trade in Venus Remedies Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Venus Remedies Ltd Share on Bajaj Broking App?

Answer Field

To buy Venus Remedies Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Venus Remedies Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader